Alterations in plasma complement levels after human ischemic stroke

J. Mocco, David A. Wilson, Ricardo J Komotar, Michael E. Sughrue, Kristen Coates, Ralph L Sacco, Mitchell S V Elkind, E. Sander Connolly

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

OBJECTIVE: Stroke is a leading cause of morbidity and mortality in the United States. Recent animal studies have implicated the complement system in cerebral ischemia/reperfusion injury and suggest that complement inhibition may improve stroke outcomes. To assess the applicability of these findings to humans, we evaluated the characteristics and time course of human complement activation after stroke. METHODS: We compared peripheral blood levels of complement factor 3a (C3a), 5a (C5a), and sC5b-9 drawn from 15 patients on poststroke Days 1, 2, 3, 7, 14, 21, and 28 to age-, race/ethnicity-, and sex-matched controls from the same population. Statistical analysis was performed using unpaired Mann-Whitney nonparametric tests with Bonferroni correction. All data is presented as the mean ± standard deviation. RESULTS: Mean C3a concentrations showed significant early elevations in stroke patients relative to matched controls (controls: 1080 ± 189 ng/ml; Day 1: 1609 ± 422 ng/ml, P = 0.0008; Day 3: 1520 ± 317 ng/ml, P = 0.0005; Day 7: 1526 ± 386 ng/ml, P = 0.001). C3a was also significantly elevated on Day 28 (1448 ± 386 ng/ml, P = 0.004). Before poststroke Day 7, mean C5a levels did not differ significantly from controls. However, beginning on Day 7 and continuing through Day 14, there were significant elevations in C5a (controls: 3.33 ± 2.1 ng/ml; day 7: 6.86 ± 3.5 ng/ml, P = 0.005; Day 14: 7.65 ± 4.6 ng/ml, P = 0.004). Mean sC5b-9 concentrations showed early depressions that reached significance on Days 1 and 2 (controls: 275.6 ± 107 ng/ml; Day 1: 167.0 ± 108 ng/ml, P = 0.006; Day 2: 156.3 ± 80.0 ng/ml, P = 0.005) and did not differ significantly from controls at any other time point. CONCLUSION: C3a is acutely elevated after human ischemic stroke, C5a shows delayed elevations 7 to 14 days after cerebral ischemia, and sC5b-9 is acutely depressed after stroke. Together, these data confirm complement activation after stroke and suggest that this activation is a heterogeneous process, with varying responses for different components.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalNeurosurgery
Volume59
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Complement C3a
Stroke
Complement Activation
Brain Ischemia
Reperfusion Injury
Morbidity
Mortality
Population

Keywords

  • Complement
  • Human
  • Ischemic
  • Plasma
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Alterations in plasma complement levels after human ischemic stroke. / Mocco, J.; Wilson, David A.; Komotar, Ricardo J; Sughrue, Michael E.; Coates, Kristen; Sacco, Ralph L; Elkind, Mitchell S V; Connolly, E. Sander.

In: Neurosurgery, Vol. 59, No. 1, 01.07.2006, p. 28-32.

Research output: Contribution to journalArticle

Mocco, J, Wilson, DA, Komotar, RJ, Sughrue, ME, Coates, K, Sacco, RL, Elkind, MSV & Connolly, ES 2006, 'Alterations in plasma complement levels after human ischemic stroke', Neurosurgery, vol. 59, no. 1, pp. 28-32. https://doi.org/10.1227/01.NEU.0000219221.14280.65
Mocco, J. ; Wilson, David A. ; Komotar, Ricardo J ; Sughrue, Michael E. ; Coates, Kristen ; Sacco, Ralph L ; Elkind, Mitchell S V ; Connolly, E. Sander. / Alterations in plasma complement levels after human ischemic stroke. In: Neurosurgery. 2006 ; Vol. 59, No. 1. pp. 28-32.
@article{39a957c1eca44e1295f932de256a4eed,
title = "Alterations in plasma complement levels after human ischemic stroke",
abstract = "OBJECTIVE: Stroke is a leading cause of morbidity and mortality in the United States. Recent animal studies have implicated the complement system in cerebral ischemia/reperfusion injury and suggest that complement inhibition may improve stroke outcomes. To assess the applicability of these findings to humans, we evaluated the characteristics and time course of human complement activation after stroke. METHODS: We compared peripheral blood levels of complement factor 3a (C3a), 5a (C5a), and sC5b-9 drawn from 15 patients on poststroke Days 1, 2, 3, 7, 14, 21, and 28 to age-, race/ethnicity-, and sex-matched controls from the same population. Statistical analysis was performed using unpaired Mann-Whitney nonparametric tests with Bonferroni correction. All data is presented as the mean ± standard deviation. RESULTS: Mean C3a concentrations showed significant early elevations in stroke patients relative to matched controls (controls: 1080 ± 189 ng/ml; Day 1: 1609 ± 422 ng/ml, P = 0.0008; Day 3: 1520 ± 317 ng/ml, P = 0.0005; Day 7: 1526 ± 386 ng/ml, P = 0.001). C3a was also significantly elevated on Day 28 (1448 ± 386 ng/ml, P = 0.004). Before poststroke Day 7, mean C5a levels did not differ significantly from controls. However, beginning on Day 7 and continuing through Day 14, there were significant elevations in C5a (controls: 3.33 ± 2.1 ng/ml; day 7: 6.86 ± 3.5 ng/ml, P = 0.005; Day 14: 7.65 ± 4.6 ng/ml, P = 0.004). Mean sC5b-9 concentrations showed early depressions that reached significance on Days 1 and 2 (controls: 275.6 ± 107 ng/ml; Day 1: 167.0 ± 108 ng/ml, P = 0.006; Day 2: 156.3 ± 80.0 ng/ml, P = 0.005) and did not differ significantly from controls at any other time point. CONCLUSION: C3a is acutely elevated after human ischemic stroke, C5a shows delayed elevations 7 to 14 days after cerebral ischemia, and sC5b-9 is acutely depressed after stroke. Together, these data confirm complement activation after stroke and suggest that this activation is a heterogeneous process, with varying responses for different components.",
keywords = "Complement, Human, Ischemic, Plasma, Stroke",
author = "J. Mocco and Wilson, {David A.} and Komotar, {Ricardo J} and Sughrue, {Michael E.} and Kristen Coates and Sacco, {Ralph L} and Elkind, {Mitchell S V} and Connolly, {E. Sander}",
year = "2006",
month = "7",
day = "1",
doi = "10.1227/01.NEU.0000219221.14280.65",
language = "English",
volume = "59",
pages = "28--32",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Alterations in plasma complement levels after human ischemic stroke

AU - Mocco, J.

AU - Wilson, David A.

AU - Komotar, Ricardo J

AU - Sughrue, Michael E.

AU - Coates, Kristen

AU - Sacco, Ralph L

AU - Elkind, Mitchell S V

AU - Connolly, E. Sander

PY - 2006/7/1

Y1 - 2006/7/1

N2 - OBJECTIVE: Stroke is a leading cause of morbidity and mortality in the United States. Recent animal studies have implicated the complement system in cerebral ischemia/reperfusion injury and suggest that complement inhibition may improve stroke outcomes. To assess the applicability of these findings to humans, we evaluated the characteristics and time course of human complement activation after stroke. METHODS: We compared peripheral blood levels of complement factor 3a (C3a), 5a (C5a), and sC5b-9 drawn from 15 patients on poststroke Days 1, 2, 3, 7, 14, 21, and 28 to age-, race/ethnicity-, and sex-matched controls from the same population. Statistical analysis was performed using unpaired Mann-Whitney nonparametric tests with Bonferroni correction. All data is presented as the mean ± standard deviation. RESULTS: Mean C3a concentrations showed significant early elevations in stroke patients relative to matched controls (controls: 1080 ± 189 ng/ml; Day 1: 1609 ± 422 ng/ml, P = 0.0008; Day 3: 1520 ± 317 ng/ml, P = 0.0005; Day 7: 1526 ± 386 ng/ml, P = 0.001). C3a was also significantly elevated on Day 28 (1448 ± 386 ng/ml, P = 0.004). Before poststroke Day 7, mean C5a levels did not differ significantly from controls. However, beginning on Day 7 and continuing through Day 14, there were significant elevations in C5a (controls: 3.33 ± 2.1 ng/ml; day 7: 6.86 ± 3.5 ng/ml, P = 0.005; Day 14: 7.65 ± 4.6 ng/ml, P = 0.004). Mean sC5b-9 concentrations showed early depressions that reached significance on Days 1 and 2 (controls: 275.6 ± 107 ng/ml; Day 1: 167.0 ± 108 ng/ml, P = 0.006; Day 2: 156.3 ± 80.0 ng/ml, P = 0.005) and did not differ significantly from controls at any other time point. CONCLUSION: C3a is acutely elevated after human ischemic stroke, C5a shows delayed elevations 7 to 14 days after cerebral ischemia, and sC5b-9 is acutely depressed after stroke. Together, these data confirm complement activation after stroke and suggest that this activation is a heterogeneous process, with varying responses for different components.

AB - OBJECTIVE: Stroke is a leading cause of morbidity and mortality in the United States. Recent animal studies have implicated the complement system in cerebral ischemia/reperfusion injury and suggest that complement inhibition may improve stroke outcomes. To assess the applicability of these findings to humans, we evaluated the characteristics and time course of human complement activation after stroke. METHODS: We compared peripheral blood levels of complement factor 3a (C3a), 5a (C5a), and sC5b-9 drawn from 15 patients on poststroke Days 1, 2, 3, 7, 14, 21, and 28 to age-, race/ethnicity-, and sex-matched controls from the same population. Statistical analysis was performed using unpaired Mann-Whitney nonparametric tests with Bonferroni correction. All data is presented as the mean ± standard deviation. RESULTS: Mean C3a concentrations showed significant early elevations in stroke patients relative to matched controls (controls: 1080 ± 189 ng/ml; Day 1: 1609 ± 422 ng/ml, P = 0.0008; Day 3: 1520 ± 317 ng/ml, P = 0.0005; Day 7: 1526 ± 386 ng/ml, P = 0.001). C3a was also significantly elevated on Day 28 (1448 ± 386 ng/ml, P = 0.004). Before poststroke Day 7, mean C5a levels did not differ significantly from controls. However, beginning on Day 7 and continuing through Day 14, there were significant elevations in C5a (controls: 3.33 ± 2.1 ng/ml; day 7: 6.86 ± 3.5 ng/ml, P = 0.005; Day 14: 7.65 ± 4.6 ng/ml, P = 0.004). Mean sC5b-9 concentrations showed early depressions that reached significance on Days 1 and 2 (controls: 275.6 ± 107 ng/ml; Day 1: 167.0 ± 108 ng/ml, P = 0.006; Day 2: 156.3 ± 80.0 ng/ml, P = 0.005) and did not differ significantly from controls at any other time point. CONCLUSION: C3a is acutely elevated after human ischemic stroke, C5a shows delayed elevations 7 to 14 days after cerebral ischemia, and sC5b-9 is acutely depressed after stroke. Together, these data confirm complement activation after stroke and suggest that this activation is a heterogeneous process, with varying responses for different components.

KW - Complement

KW - Human

KW - Ischemic

KW - Plasma

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33745803889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745803889&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000219221.14280.65

DO - 10.1227/01.NEU.0000219221.14280.65

M3 - Article

C2 - 16823297

AN - SCOPUS:33745803889

VL - 59

SP - 28

EP - 32

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -